AbbVie (ABBV) is poised for a pivotal moment as it prepares to report earnings on April 29, following a challenging start to the year with a 10% decline in stock price. Despite facing headwinds from the loss of patent protection on its flagship drug, Humira, AbbVie has successfully diversified its portfolio with strong performances from newer drugs like Skyrizi and Rinvoq, and strategic acquisitions that have bolstered its growth trajectory.
The company’s adjusted diluted earnings per share (EPS) projections for this year range between $13.96 and $14.16, a notable increase from $10.00 in 2025. While AbbVie’s current price-to-earnings ratio appears high at 88, it reflects one-time acquisition expenses; analysts suggest a more favorable forward multiple of 14, indicating potential undervaluation.
For market professionals, AbbVie presents an attractive opportunity, combining robust growth prospects with a reliable dividend yield of 3.3%, significantly above the S&P 500 average. A strong earnings report could reaffirm AbbVie’s position as a solid long-term investment.
Source: fool.com